| Name | Title | Contact Details |
|---|
Ben Venue Laboratories is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CTMG is a Greenville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vitae Pharmaceuticals, Inc. focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer's disease. The company’s products in preclinical studies comprise VTP-43742 for the treatment of autoimmune disorders, such as psoriasis, multiple sclerosis, rheumatoid arthritis, Behcet's disease, and autoimmune uveitis; VTP-38443 for the treatment of acute coronary syndrome that consists of unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. Vitae Pharmaceuticals, Inc. has collaborations with Boehringer Ingelheim GmbH for the development of VTP-34072 and VTP-37948. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January, 2005. The company was founded in 2001 and is headquartered in Fort Washington, Pennsylvania.
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine.
Terumo Heart, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.